Assessment of Quality of Life and Safety in Postmenopausal Breast Cancer Patients Receiving Letrozole as an Early Adjuvant Treatment
- 주제(키워드) Breast neoplasms , Letrozole , Quality of life , Treatment
- 주제(기타) Oncology
- 설명문(일반) [Jung, Yongsik; Han, Sehwan] Ajou Univ, Dept Surg, Sch Med, 206 World Cup Ro, Suwon 16499, South Korea; [Lee, Soo Jung] Yeungnam Univ Hosp, Dept Surg, Daegu, South Korea; [Lee, Juneyoung] Korea Univ, Dept Biostat, Coll Med, Seoul, South Korea; [Noh, Woo Chul] Korea Inst Radiol & Med Sci, Dept Surg, Seoul, South Korea; [Nam, Seok Jin] Samsung Med Ctr, Dept Surg, Seoul, South Korea; [Park, Byeong-Woo; Cho, Young Up] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea; [Bae, Young Tae] Pusan Natl Univ, Sch Med, Dept Surg, Busan, South Korea; [Kang, Sung-Soo] Dankook Univ, Dept Surg, Cheil Gen Hosp, Coll Med, Seoul, South Korea; [Kang, Sung-Soo] Dankook Univ, Womens Healthcare Ctr, Coll Med, Seoul, South Korea; [Parks, Heung Kyu] Gachon Univ, Gil Hosp, Dept Surg, Incheon, South Korea; [Yoon, Jung-Han] Chonnam Natl Univ, Dept Surg, Hwasun Hosp, Hwasun, South Korea; [Kim, Je Ryong] Chungnam Natl Univ Hosp, Dept Surg, Daejeon, South Korea; [Cho, Se Hun] Dong A Univ Hosp, Dept Surg, Busan, South Korea; [Kim, Lee Su] Hallym Univ, Dept Surg, Coll Med, Anyang, South Korea; [Moon, Byung In] Ewha Womans Univ Hosp, Breast Canc Ctr, Seoul, South Korea; [Jung, Sung Hoo] Chonbuk Natl Univ, Dept Surg, Med Sch, Jeonju, South Korea; [Lim, Chol Wan] Soonchunhyang Univ, Bucheon Hosp, Dept Surg, Bucheon, South Korea; [Kim, Sung Yong] Soonchunhyang Univ, Cheonan Hosp, Dept Surg, Cheonan, South Korea; [Park, Ho Yong] Kyungpook Natl Univ, Dept Surg, Med Ctr, Daegu, South Korea; [Song, Jeongyoon] Kyung Hee Univ Hosp Gangdong, Dept Surg, Seoul, South Korea; [Lee, Kwang Man] Wonkwang Univ Hosp, Dept Surg, Iksan, South Korea; [Park, Sung Hwan] Daegu Catholic Univ Hosp, Dept Surg, Daegu, South Korea; [Jeong, Joon] Yonsei Univ, Gangnam Severance Hosp, Dept Surg, Seoul, South Korea; [Park, Hae Lin] CHA Gangnam Med Ctr, Dept Surg, Seoul, South Korea; [Kim, Sung Won] Daerim St Marys Hosp, Dept Surg, Seoul, South Korea; [Kwak, Beom Seok] Dongguk Univ, Ilsan Hosp, Dept Surg, Goyang, South Korea; [Kang, Sun Hee] Keimyung Univ, Sch Med, Dept Surg, Daegu, South Korea; [Gwak, Geum Hee] Inje Univ, Sanggye Paik Hosp, Dept Surg, Seoul, South Korea; [Park, Yong Lae] Kangbuk Samsung Hosp, Dept Surg, Seoul, South Korea; [Kim, Sang Wook] Bundang Jesaeng Hosp, Dept Surg, Seongnam, South Korea
- 등재 SCIE, SCOPUS, KCI등재
- 발행기관 KOREAN BREAST CANCER SOC
- 발행년도 2018
- URI http://www.dcollection.net/handler/ewha/000000151457
- 본문언어 영어
- Published As http://dx.doi.org/10.4048/jbc.2018.21.2.182
초록/요약
Purpose: There are few reports from Asian countries about the long-term results of aromatase inhibitor adjuvant treatment for breast cancer. This observational study aimed to evaluate the long-term effects of letrozole in postmenopausal Korean women with operable breast cancer. Methods: Self-reported quality of life (QoL) scores were serially assessed for 3 years during adjuvant letrozole treatment using the Korean version of the Functional Assessment of Cancer Therapy-Breast questionnaires (version 3). Changes in bone mineral density (BMD) and serum cholesterol levels were also examined. Results: All 897 patients received the documented informed consent form and completed a baseline questionnaire before treatment. Adjuvant chemotherapy was administered to 684 (76.3%) subjects, and 410 (45.7%) and 396 (44.1%) patients had stage I and II breast cancer, respectively. Each patient completed questionnaires at 3, 6, 12, 18, 24, 30, and 36 months after enrollment. Of 897 patients, 749 (83.5%) completed the study. The dropout rate was 16.5%. The serial trial outcome index, the sum of the physical and functional well-being subscales, increased gradually and significantly from baseline during letrozole treatment (p<0.001). The mean serum cholesterol level increased significantly from 199 to 205 after 36 months (p = 0.042). The mean BMD significantly decreased from -0.39 at baseline to -0.87 after 36 months (p<0.001). Conclusion: QoL gradually improved during letrozole treatment. BMD and serum cholesterol level changes were similar to those in Western countries, indicating that adjuvant letrozole treatment is well tolerated in Korean women, with minimal ethnic variation.
more